Novogen (KZIA) Stock Price, News & Analysis

Company Overview

Novogen Limited, now known as Kazia Therapeutics Limited, is an Australia-based biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on targeted treatments designed to address tumors that are difficult to treat with conventional approaches.

Kazia’s principal clinical program has been paxalisib, an orally administered inhibitor of the PI3K/mTOR pathway being investigated primarily for brain cancers, including glioblastoma. The company has also pursued other oncology candidates, including therapies intended to inhibit tumor growth and angiogenesis.

Founded in Australia, Novogen developed its early drug-discovery and oncology programs before changing its name to Kazia Therapeutics in 2016. The company’s activities have included collaborations and clinical development programs involving research institutions and trial sites in Australia, the United States, and other international markets.

Key Stats

• Today's Range: $9.12 to $9.74
• 50-Day Range: $9.27 to $16.90
• 52-Week Range: $4.86 to $17.40
• Volume: 128,651 shs
• Average Volume: 288,963 shs
• Market Capitalization: $120.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.80
• Consensus Rating: Moderate Buy

Novogen Stock Analysis - MarketRank™

Novogen scored higher than 66% of companies evaluated by MarketBeat, and ranked 197th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Novogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Novogen has a consensus price target of $28.80, representing about 210.7% upside from its current price of $9.27.

Amount of Analyst Coverage

Novogen has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.99% of the float of Novogen has been sold short.

Short Interest Ratio / Days to Cover

Novogen has a short interest ratio ("days to cover") of 2.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novogen has recently decreased by 15.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novogen does not currently pay a dividend.

Dividend Growth

Novogen does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for KZIA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Novogen is held by insiders.

Percentage Held by Institutions

30.89% of the stock of Novogen is held by institutions.

Company Calendar

• Today: 10/04/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KZIA
• Previous Symbol: ASX:KZA
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 6
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Novogen: $28.80
• High Price Target: $40.00
• Low Price Target: $18.00
• Potential Upside/Downside: +210.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.23 million
• Price / Sales: 97.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.34) per share
• Price / Book: -1.74

Miscellaneous

• Outstanding Shares: 12,970,000
• Free Float: 12,839,000
• Market Cap: $120.23 million
• Optionable: No Data
• Beta: 2.26